Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy
Authors:
Open Access
- 17 March 2021
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-23
Abstract
Background: Transgelin-2 is a 22 kDa actin-binding protein that has been proposed to act as an oncogenic factor, capable of contributing to tumorigenesis in a wide range of human malignancies. However, little is known whether this tiny protein also plays an important role in immunity, thereby keeping body from the cancer development and metastasis. Here, we investigated the functions of transgelin-2 in dendritic cell (DC) immunity. Further, we investigated whether the non-viral transduction of cell-permeable transgelin-2 peptide potentially enhance DC-based cancer immunotherapy. Methods: To understand the functions of transgelin-2 in DCs, we utilized bone marrow-derived DCs (BMDCs) purified from transgelin-2 knockout (Tagln2−/−) mice. To observe the dynamic cellular mechanism of transgelin-2, we utilized confocal microscopy and flow cytometry. To monitor DC migration and cognate T–DC interaction in vivo, we used intravital two-photon microscopy. For the solid and metastasis tumor models, OVA+ B16F10 melanoma were inoculated into the C57BL/6 mice via intravenously (i.v.) and subcutaneously (s.c.), respectively. OTI TCR T cells were used for the adoptive transfer experiments. Cell-permeable, de-ubiquitinated recombinant transgelin-2 was purified from Escherichia coli and applied for DC-based adoptive immunotherapy. Results: We found that transgelin-2 is remarkably expressed in BMDCs during maturation and lipopolysaccharide activation, suggesting that this protein plays a role in DC-based immunity. Although Tagln2−/− BMDCs exhibited no changes in maturation, they showed significant defects in their abilities to home to draining lymph nodes (LNs) and prime T cells to produce antigen-specific T cell clones, and these changes were associated with a failure to suppress tumor growth and metastasis of OVA+ B16F10 melanoma cells in mice. Tagln2−/− BMDCs had defects in filopodia-like membrane protrusion and podosome formation due to the attenuation of the signals that modulate actin remodeling in vitro and formed short, unstable contacts with cognate CD4+ T cells in vivo. Strikingly, non-viral transduction of cell-permeable, de-ubiquitinated recombinant transgelin-2 potentiated DC functions to suppress tumor growth and metastasis. Conclusion: This work demonstrates that transgelin-2 is an essential protein for both cancer and immunity. Therefore, transgelin-2 can act as a double-edged sword depending on how we apply this protein to cancer therapy. Engineering and clinical application of this protein may unveil a new era in DC-based cancer immunotherapy. Our findings indicate that cell-permeable transgelin-2 have a potential clinical value as a cancer immunotherapy based on DCs.Keywords
Funding Information
- Ministry of Science and ICT (2015R1A3A2066253, 2020M3A9G3080281)
- Ministry of Education (2019R1C1C1009570)
- Ministry of Health and Welfare (1911264)
- Gwangju Institute of Science and Technology (IBBR grant)
This publication has 46 references indexed in Scilit:
- Proteomic analysis of differential protein expression by brain metastases of gynecological malignanciesHuman Cell, 2013
- The Actin Regulatory Protein HS1 Is Required for Antigen Uptake and Presentation by Dendritic CellsThe Journal of Immunology, 2011
- Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancerJournal of Cancer Research and Clinical Oncology, 2011
- Hematopoietic Lineage Cell-Specific Protein 1 Functions in Concert with the Wiskott–Aldrich Syndrome Protein To Promote Podosome Array Organization and Chemotaxis in Dendritic CellsThe Journal of Immunology, 2011
- Rho-mDia1 pathway is required for adhesion, migration, and T-cell stimulation in dendritic cellsBlood, 2010
- Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cellsJournal of Experimental Medicine, 2010
- The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cellsJournal of Experimental Medicine, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensJournal of Experimental Medicine, 2010
- TLR ligand–induced podosome disassembly in dendritic cells is ADAM17 dependentJournal of Cell Biology, 2008
- Mechanisms and Consequences of Dendritic Cell MigrationImmunity, 2008